JP2023525695A5 - - Google Patents

Info

Publication number
JP2023525695A5
JP2023525695A5 JP2022566612A JP2022566612A JP2023525695A5 JP 2023525695 A5 JP2023525695 A5 JP 2023525695A5 JP 2022566612 A JP2022566612 A JP 2022566612A JP 2022566612 A JP2022566612 A JP 2022566612A JP 2023525695 A5 JP2023525695 A5 JP 2023525695A5
Authority
JP
Japan
Prior art keywords
seq
binding domain
acid sequences
amino acid
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022566612A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2021/050506 external-priority patent/WO2021224913A1/en
Publication of JP2023525695A publication Critical patent/JP2023525695A/ja
Publication of JP2023525695A5 publication Critical patent/JP2023525695A5/ja
Pending legal-status Critical Current

Links

JP2022566612A 2020-05-04 2021-05-04 前駆体三重特異性抗体構築物及びその使用方法 Pending JP2023525695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063019443P 2020-05-04 2020-05-04
US63/019,443 2020-05-04
US202063026143P 2020-05-18 2020-05-18
US63/026,143 2020-05-18
PCT/IL2021/050506 WO2021224913A1 (en) 2020-05-04 2021-05-04 Precursor tri-specific antibody constructs and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023525695A JP2023525695A (ja) 2023-06-19
JP2023525695A5 true JP2023525695A5 (cg-RX-API-DMAC10.html) 2024-04-24

Family

ID=76076399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022566612A Pending JP2023525695A (ja) 2020-05-04 2021-05-04 前駆体三重特異性抗体構築物及びその使用方法

Country Status (11)

Country Link
US (1) US20230312753A1 (cg-RX-API-DMAC10.html)
EP (1) EP4146695A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023525695A (cg-RX-API-DMAC10.html)
KR (1) KR20230005952A (cg-RX-API-DMAC10.html)
CN (1) CN116096754A (cg-RX-API-DMAC10.html)
AU (1) AU2021267953A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022022369A2 (cg-RX-API-DMAC10.html)
CA (1) CA3181963A1 (cg-RX-API-DMAC10.html)
IL (1) IL297412A (cg-RX-API-DMAC10.html)
MX (1) MX2022013876A (cg-RX-API-DMAC10.html)
WO (1) WO2021224913A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
EP4304726A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Mage-a4 peptide-mhc antigen binding proteins
US20240228626A1 (en) * 2021-05-04 2024-07-11 Immunorizon Ltd. Anti-nkg2d antibodies and uses thereof
MX2023013018A (es) * 2021-05-04 2024-01-18 Immunorizon Ltd Anticuerpos anti-5t4 y usos de estos.
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
CA3241115A1 (en) * 2021-12-14 2023-06-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd94/nkg2a heterodimer polypeptides
EP4587046A1 (en) 2022-09-14 2025-07-23 CDR-Life AG Mage-a4 peptide dual t cell engagers
CN122349537A (zh) * 2023-12-01 2026-07-07 阿布林克斯有限公司 识别人血清白蛋白、tcr和肿瘤抗原识别部分的多特异性抗体

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP0737207B1 (en) 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
AU2004242845B2 (en) 2003-05-31 2011-06-02 Amgen Research (Munich) Gmbh Human-anti-human CD3 binding molecules
ATE423140T1 (de) 2005-01-05 2009-03-15 F Star Biotech Forsch & Entw Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP1829895A1 (en) 2006-03-03 2007-09-05 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies
DK2038306T3 (en) * 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CN101319011B (zh) * 2007-06-04 2010-11-10 中国人民解放军军事医学科学院基础医学研究所 多型别hcv-e1表位复合免疫原及其编码基因与应用
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
US8778329B2 (en) 2009-03-04 2014-07-15 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
JP5593641B2 (ja) 2009-06-26 2014-09-24 味の素株式会社 減塩飲食品用組成物
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
MX342131B (es) * 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
BR112015000798A2 (pt) * 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
AU2015316993B2 (en) * 2014-09-16 2021-03-18 Innate Pharma Treatment regimens using anti-NKG2A antibodies
EP3197916A2 (en) 2014-09-25 2017-08-02 Amgen Inc. Protease-activatable bispecific proteins
US11053293B2 (en) * 2016-02-05 2021-07-06 Washington University Compositions and methods for targeted cytokine delivery
WO2017157305A1 (en) * 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
WO2017162587A1 (en) 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CN111787949A (zh) * 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
CN112119093A (zh) * 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
WO2019222282A1 (en) * 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
WO2019219658A1 (en) * 2018-05-15 2019-11-21 Medimmune Limited Treatment of cancer
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
WO2020023553A1 (en) * 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020084608A1 (en) * 2018-10-22 2020-04-30 Explore Bio 1 Ltd Precursor bispecific antibody constructs and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2025160458A5 (cg-RX-API-DMAC10.html)
JP2024020298A5 (cg-RX-API-DMAC10.html)
JP2022533538A5 (cg-RX-API-DMAC10.html)
JP2021534096A5 (cg-RX-API-DMAC10.html)
CN115052893A (zh) 抗tigit抗体和使用方法
JP2021521843A5 (cg-RX-API-DMAC10.html)
JP2020510422A5 (cg-RX-API-DMAC10.html)
JP2023540526A5 (cg-RX-API-DMAC10.html)
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
JP2020514277A5 (cg-RX-API-DMAC10.html)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
JP2021533159A5 (cg-RX-API-DMAC10.html)
RU2013142600A (ru) Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы
JP2024527288A5 (cg-RX-API-DMAC10.html)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2024024114A5 (cg-RX-API-DMAC10.html)
JP2021512652A5 (cg-RX-API-DMAC10.html)
JP2024540148A5 (cg-RX-API-DMAC10.html)
JP2020513759A5 (cg-RX-API-DMAC10.html)
JP2023506834A5 (cg-RX-API-DMAC10.html)
JP2023520969A5 (cg-RX-API-DMAC10.html)
KR20250065933A (ko) 표적 세포-의존적 T 세포 관여 및 활성화 비대칭 헤테로다이머 Fc-ScFv 융합 항체 포맷 및 암 치료에서 그 사용
JP2022517216A5 (cg-RX-API-DMAC10.html)
JP2025511288A (ja) 抗pvrig抗体、その医薬組成物及びその使用